DK3860990T3 - Inhibitorer for YAP/TAZ-TEAD interaktion og disses anvendelse ved behandlingen af cancer - Google Patents
Inhibitorer for YAP/TAZ-TEAD interaktion og disses anvendelse ved behandlingen af cancer Download PDFInfo
- Publication number
- DK3860990T3 DK3860990T3 DK19782584.7T DK19782584T DK3860990T3 DK 3860990 T3 DK3860990 T3 DK 3860990T3 DK 19782584 T DK19782584 T DK 19782584T DK 3860990 T3 DK3860990 T3 DK 3860990T3
- Authority
- DK
- Denmark
- Prior art keywords
- yap
- taz
- inhibitors
- cancer
- treatment
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 230000003993 interaction Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
- C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Testing Relating To Insulation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18306294.2A EP3632908A1 (en) | 2018-10-02 | 2018-10-02 | Inhibitors of the yap/taz-tead interaction and their use in the treatment of cancer |
| PCT/EP2019/076681 WO2020070181A1 (en) | 2018-10-02 | 2019-10-02 | Inhibitors of the yap/taz-tead interaction and their use in the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3860990T3 true DK3860990T3 (da) | 2022-12-19 |
Family
ID=63857833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK19782584.7T DK3860990T3 (da) | 2018-10-02 | 2019-10-02 | Inhibitorer for YAP/TAZ-TEAD interaktion og disses anvendelse ved behandlingen af cancer |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US11999758B2 (da) |
| EP (2) | EP3632908A1 (da) |
| JP (1) | JP7430715B2 (da) |
| KR (1) | KR102693917B1 (da) |
| CN (1) | CN113039182B (da) |
| AU (1) | AU2019352009B2 (da) |
| BR (1) | BR112021006229A2 (da) |
| DK (1) | DK3860990T3 (da) |
| ES (1) | ES2931150T3 (da) |
| HU (1) | HUE059965T2 (da) |
| IL (1) | IL281999B2 (da) |
| MX (1) | MX2021003843A (da) |
| PL (1) | PL3860990T3 (da) |
| PT (1) | PT3860990T (da) |
| SI (1) | SI3860990T1 (da) |
| UA (1) | UA128980C2 (da) |
| WO (1) | WO2020070181A1 (da) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11787775B2 (en) | 2020-07-24 | 2023-10-17 | Genentech, Inc. | Therapeutic compounds and methods of use |
| EP4222143A1 (en) | 2020-09-30 | 2023-08-09 | Katholieke Universiteit Leuven | 1,2,3,4-tetrahydroquinoline derivatives as inhibitors of the yap/taz-tead activation for treating cancer |
| AR125350A1 (es) | 2021-04-16 | 2023-07-12 | Orion Corp | Inhibidores tead |
| WO2023042901A1 (ja) * | 2021-09-16 | 2023-03-23 | 慶應義塾 | 小細胞肺癌患者ｃｔｃ由来オルガノイド製造と小細胞肺癌分子標的治療薬としてのｉｇｆ１ｒ阻害剤 |
| WO2023122780A2 (en) | 2021-12-23 | 2023-06-29 | The Katholieke Universiteit Leuven | 2-pyrazole anilines and related analogs for inhibiting yap/taz-tead |
| WO2023150619A2 (en) * | 2022-02-02 | 2023-08-10 | The Katholieke Universiteit Leuven | Tetrahydropyridopyrimidines and related analogs for inhibiting yap/taz-tead |
| AU2023349151A1 (en) | 2022-09-29 | 2025-04-03 | Insilico Medicine Ip Limited | Tead inhibitors and methods of uses thereof |
| CN121712509A (zh) | 2023-05-04 | 2026-03-20 | 锐新医药公司 | 用于ras相关疾病或病症的组合疗法 |
| CN116239498B (zh) * | 2023-05-11 | 2023-07-21 | 北京元延医药科技股份有限公司 | 制备克立硼罗中间体的方法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| IL327306A (en) | 2023-10-12 | 2026-05-01 | Revolution Medicines Inc | Macrocyclic RAS inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5306818A (en) | 1990-11-01 | 1994-04-26 | Sterling Winthrop Inc. | Tetrahydro 2-saccharinylmerthyl aryl carboxylates |
| US6200957B1 (en) | 1995-12-14 | 2001-03-13 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| US6011034A (en) | 1998-02-12 | 2000-01-04 | Uniroyal Chemical Company, Inc. | Insecticidal dihydrooxadiazine compounds |
| DE60304718T2 (de) | 2002-08-06 | 2007-04-26 | Astrazeneca Ab | Kondensierte pyridine und pyrimidine mit tie2 (tek) aktivität |
| EP2258365B1 (en) | 2003-03-28 | 2013-05-29 | Novartis Vaccines and Diagnostics, Inc. | Use of organic compounds for immunopotentiation |
| KR20080048550A (ko) | 2005-09-23 | 2008-06-02 | 메모리 파마슈티칼스 코포레이션 | 인다졸, 벤조티아졸, 벤조이소티아졸, 벤즈이속사졸,피라졸로피리딘, 이소티아졸로피리딘, 및 이들의 제법 및용도 |
| JO3598B1 (ar) * | 2006-10-10 | 2020-07-05 | Infinity Discovery Inc | الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني |
| US20100160424A1 (en) | 2007-06-20 | 2010-06-24 | Baldwin John J | Renin inhibitors |
| WO2009029998A1 (en) | 2007-09-06 | 2009-03-12 | Cytopia Research Pty Ltd | Retrometabolic compounds |
| AU2008323628B2 (en) | 2007-11-15 | 2013-10-17 | Ym Biosciences Australia Pty Ltd | N-containing heterocyclic compounds |
| WO2010074284A1 (ja) * | 2008-12-26 | 2010-07-01 | 味の素株式会社 | ピラゾロピリミジン化合物 |
| FR2942797B1 (fr) | 2009-03-03 | 2011-04-29 | Pf Medicament | Derives de benzothiazines, leur preparation et leur application a titre de medicaments |
| EP2397482A1 (en) | 2010-06-15 | 2011-12-21 | Almirall, S.A. | Heteroaryl imidazolone derivatives as jak inhibitors |
| PH12013501126A1 (en) | 2010-12-21 | 2022-03-30 | Janssen Pharmaceutica Nv | NOVEL ANTIFUNGAL 5,6-DIHYDRO-4H-PYRROLO[1,2-a][1,4]- BENZODIAZEPINES AND 6H-PYRROLO[1,2-a][1,4]BENZODIAZEPINES SUBSTITUTED WITH BICYCLIC BENZENE DERIVATIVES |
| EP2592077A1 (en) | 2011-11-11 | 2013-05-15 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities |
| CA2855446C (en) | 2011-11-23 | 2021-04-20 | Cancer Research Technology Limited | Thienopyrimidine inhibitors of atypical protein kinase c |
| WO2013123071A1 (en) | 2012-02-13 | 2013-08-22 | Cleave Biosciences, Inc. | Methods and compositions for jamm protease inhibition |
| ES2689541T3 (es) | 2012-06-19 | 2018-11-14 | Rutgers, The State University Of New Jersey | Agentes antibacterianos: derivados de aril mixopironina |
| WO2014025942A1 (en) | 2012-08-09 | 2014-02-13 | Emory University | Nmda receptor modulators and uses related thereto |
| US8906929B2 (en) | 2012-08-16 | 2014-12-09 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| EP2921480B1 (en) | 2012-11-19 | 2017-10-11 | Takeda Pharmaceutical Company Limited | Nitrogen-containing heterocyclic compound |
| US9458124B2 (en) | 2013-02-06 | 2016-10-04 | Wayne State University | Substituted pyran derivatives |
| CN105658640A (zh) | 2013-08-22 | 2016-06-08 | 豪夫迈·罗氏有限公司 | 炔基醇和应用方法 |
| WO2015097237A1 (en) * | 2013-12-23 | 2015-07-02 | Syngenta Participations Ag | Benzoxaborole fungicides |
| PE20171057A1 (es) | 2014-10-08 | 2017-07-21 | Hoffmann La Roche | Derivados espirodiamina como inhibidores de la aldosterona sintasa |
| PL3240785T3 (pl) | 2014-12-29 | 2021-12-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inhibitory drobnocząsteczkowe dehydrogenazy mleczanowej i sposoby ich wykorzystania |
| EP3353156B1 (en) * | 2015-09-23 | 2021-11-03 | The General Hospital Corporation | Tead transcription factor autopalmitoylation inhibitors |
| EP3156404A1 (en) * | 2015-10-15 | 2017-04-19 | Inventiva | New compounds inhibitors of the yap/taz-tead interaction and their use in the treatment of malignant mesothelioma |
| CN107709288A (zh) | 2016-02-03 | 2018-02-16 | 四川海思科制药有限公司 | 一种磷酰胺衍生物及制备方法和用途 |
| CN109912609A (zh) * | 2017-12-12 | 2019-06-21 | 江苏三月光电科技有限公司 | 一种以含氮五元杂环为母核的化合物及其在有机电致发光器件上的应用 |
-
2018
- 2018-10-02 EP EP18306294.2A patent/EP3632908A1/en not_active Withdrawn
-
2019
- 2019-10-02 BR BR112021006229A patent/BR112021006229A2/pt not_active IP Right Cessation
- 2019-10-02 PT PT197825847T patent/PT3860990T/pt unknown
- 2019-10-02 DK DK19782584.7T patent/DK3860990T3/da active
- 2019-10-02 US US17/278,429 patent/US11999758B2/en active Active
- 2019-10-02 ES ES19782584T patent/ES2931150T3/es active Active
- 2019-10-02 EP EP19782584.7A patent/EP3860990B1/en active Active
- 2019-10-02 IL IL281999A patent/IL281999B2/en unknown
- 2019-10-02 UA UAA202101719A patent/UA128980C2/uk unknown
- 2019-10-02 WO PCT/EP2019/076681 patent/WO2020070181A1/en not_active Ceased
- 2019-10-02 KR KR1020217011255A patent/KR102693917B1/ko active Active
- 2019-10-02 JP JP2021518089A patent/JP7430715B2/ja active Active
- 2019-10-02 CN CN201980075645.2A patent/CN113039182B/zh active Active
- 2019-10-02 HU HUE19782584A patent/HUE059965T2/hu unknown
- 2019-10-02 AU AU2019352009A patent/AU2019352009B2/en not_active Ceased
- 2019-10-02 SI SI201930344T patent/SI3860990T1/sl unknown
- 2019-10-02 MX MX2021003843A patent/MX2021003843A/es unknown
- 2019-10-02 PL PL19782584.7T patent/PL3860990T3/pl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2931150T3 (es) | 2022-12-27 |
| UA128980C2 (uk) | 2024-12-18 |
| PT3860990T (pt) | 2022-10-18 |
| PL3860990T3 (pl) | 2023-01-23 |
| SI3860990T1 (sl) | 2022-11-30 |
| KR102693917B1 (ko) | 2024-08-09 |
| EP3860990A1 (en) | 2021-08-11 |
| BR112021006229A2 (pt) | 2021-07-06 |
| WO2020070181A1 (en) | 2020-04-09 |
| IL281999A (en) | 2021-05-31 |
| IL281999B1 (en) | 2023-11-01 |
| US11999758B2 (en) | 2024-06-04 |
| AU2019352009A1 (en) | 2021-04-15 |
| HUE059965T2 (hu) | 2023-01-28 |
| CN113039182A (zh) | 2021-06-25 |
| CA3114375A1 (en) | 2020-04-09 |
| US20210323982A1 (en) | 2021-10-21 |
| KR20210072001A (ko) | 2021-06-16 |
| CN113039182B (zh) | 2024-02-20 |
| AU2019352009B2 (en) | 2024-04-04 |
| MX2021003843A (es) | 2021-05-27 |
| IL281999B2 (en) | 2024-03-01 |
| JP7430715B2 (ja) | 2024-02-13 |
| EP3860990B1 (en) | 2022-09-14 |
| JP2022504077A (ja) | 2022-01-13 |
| EP3632908A1 (en) | 2020-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL281999A (en) | YAP/TAZ-TEAD interaction inhibitors and their use in cancer therapy | |
| DK3678668T3 (da) | ENPP1-inhibitorer og deres anvendelse til behandling af kræft | |
| DK3612517T3 (da) | Bicykliske forbindelser og deres anvendelse ved behandling af cancer | |
| IL283149A (en) | 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer | |
| PT3902803T (pt) | Inibidores aza-heterobicíclicos de mat2a e métodos de utilização para o tratamento do cancro | |
| DK3849534T3 (da) | Kombination af dasatinib og adagrasib til anvendelse i behandling af ikke-småcellet lungecancer | |
| IL282663A (en) | Bt1718 for use in treating cancer | |
| DK3558997T3 (da) | Aminotriazolopyridinforbindelser og deres anvendelse til behandling af cancer | |
| IL261721A (en) | Combinations of lsd1 inhibitors for use in the treatment of solid tumors | |
| DK3285809T3 (da) | Inhibitorer af immunkontrolpunktsmodulatorer til anvendelse i behandling af kræft og infektioner. | |
| DK3331900T3 (da) | Peptider og kombination af peptider til anvendelse ved immunterapi mod prostatacancer og andre cancere | |
| DK3842429T3 (da) | Heterocykliske inhibitorer af ERK1 og ERK2 og anvendelse deraf i behandling af cancer | |
| DK3368069T3 (da) | Anvendelse af myostatininhibitorer og kombinationsterapier | |
| DK4010329T3 (da) | Deutererede forbindelser til anvendelse ved behandling af cancer | |
| DK3416957T3 (da) | 6-heterocyclyl-4-morpholin-4-ylpyridin-2-on-forbindelser anvendelige ved behandlingen af cancer og diabetes | |
| DK3790879T3 (da) | Triazolopyrimidinforbindelser og deres anvendelse til behandling af kræft | |
| DK3939658T3 (da) | Substitueret benzopyrrol og strukturelt relaterede komplementinhibitorer | |
| DK3806898T3 (da) | Gremlin-1-antagonist til anvendelse i behandling af cancer | |
| DK3325488T3 (da) | Chiral diaryl-makrocyklus og anvendelse deraf til behandling af cancer | |
| DK3336197T3 (da) | Epigenetiske markører og relaterede fremgangsmåder og midler til detektion og behandling af ovariekræft | |
| DK3416945T3 (da) | 6-aryl-4-(morpholin-4-yl)-1h-pyridin-2-on-forbindelser anvendelige ved behandlingen af cancer og diabetes | |
| DK3293201T3 (da) | Kombinering af adenovirus og checkpoint-inhibitorer til behandling af cancer | |
| DK3601296T3 (da) | 2-oxo-thiazolderivater som a2a-inhibitorer og forbindelser til anvendelse ved behandling af cancere | |
| DK3807316T3 (da) | Sammensætninger og fremgangsmåder til behandling af cancer | |
| IL283899A (en) | Combinations of a hdm2-p53 interaction inhibitor and a bcl2 inhibitor and their use for treating cancer |